Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration
Purpose To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD). Methods This was a retrospective, longitudinal, cross-sectional study including patients...
Gespeichert in:
| Veröffentlicht in: | European journal of ophthalmology 2017-03, Vol.27 (2), p.196-200 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 200 |
|---|---|
| container_issue | 2 |
| container_start_page | 196 |
| container_title | European journal of ophthalmology |
| container_volume | 27 |
| creator | Hernández-Martínez, Pablo Dolz-Marco, Rosa Hervás-Marín, David Andreu-Fenoll, Maria Gallego-Pinazo, Roberto Arévalo, José Fernando |
| description | Purpose
To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD).
Methods
This was a retrospective, longitudinal, cross-sectional study including patients diagnosed with nAMD type 1 lesions managed with intravitreal injections of ranibizumab in a PRN strategy during 24 months. Retrospective chart review of patients with type 1 CNV recording the visual acuity, number of intravitreal injections, multimodal imaging data, and follow-up period was performed. Subfoveal choroidal thickness was measured using enhanced depth imaging scans obtained with spectral-domain optical coherence tomography.
Results
Twenty-five eyes of 21 patients were included. The mean baseline logMAR best-corrected visual acuity was 0.52 (+0.35) (median 0.5; range 0.1-1; interquartile range (IQR) 0.3-0.8) and improved to 0.39 (+0.39) (median 0.4; range 0.1-1; IQR 0.2-0.5) by the end of the follow-up (p = 0.038). Subfoveal choroidal thickness was 202.8 (+60.3) μm (median 218; range 81-285; IQR 146-258). Statistical mixed effects model demonstrated an association between rate of improvement of visual acuity with subfoveal choroidal thickness after 24 months (p |
| doi_str_mv | 10.5301/ejo.5000860 |
| format | Article |
| fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_5301_ejo_5000860</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.5301_ejo.5000860</sage_id><sourcerecordid>10.5301_ejo.5000860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-8cde630724b429bf337daeef68df4d671fedfaf277ef9b973c2d74c8c71167283</originalsourceid><addsrcrecordid>eNptkEtPwzAQhC0EoqVw4o58REIptpPaybFqy0MqD6HCNXLsdZqSxpWdIPXfY5TCidOuVt-OZgahS0rGk5jQW9jY8YQQknJyhIZUsCTihPLjsFNGIi4YHaAz7zeEMJIl7BQNmOAJj2MxRNvZ2jpbaVnj1bpSnw14j2Wj8Uflu3B8dbZsrK88rhq82u8AU7wEX9kGzzvArcXPYL-kV10tHZ6WEL1BLVvQ-En2tzmU0ICTbfg5RydG1h4uDnOE3u8Wq9lDtHy5f5xNl5GKGWujVGngMQlJioRlhQlOtQQwPNUm0VxQA9pIw4QAkxWZiBXTIlGpEpSGuGk8Qje9rnLWewcm37lqK90-pyT_KS0PpeWH0gJ91dO7rtiC_mN_WwrAdQ94WUK-sZ1rgvt_tb4BbyN1jA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Hernández-Martínez, Pablo ; Dolz-Marco, Rosa ; Hervás-Marín, David ; Andreu-Fenoll, Maria ; Gallego-Pinazo, Roberto ; Arévalo, José Fernando</creator><creatorcontrib>Hernández-Martínez, Pablo ; Dolz-Marco, Rosa ; Hervás-Marín, David ; Andreu-Fenoll, Maria ; Gallego-Pinazo, Roberto ; Arévalo, José Fernando</creatorcontrib><description>Purpose
To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD).
Methods
This was a retrospective, longitudinal, cross-sectional study including patients diagnosed with nAMD type 1 lesions managed with intravitreal injections of ranibizumab in a PRN strategy during 24 months. Retrospective chart review of patients with type 1 CNV recording the visual acuity, number of intravitreal injections, multimodal imaging data, and follow-up period was performed. Subfoveal choroidal thickness was measured using enhanced depth imaging scans obtained with spectral-domain optical coherence tomography.
Results
Twenty-five eyes of 21 patients were included. The mean baseline logMAR best-corrected visual acuity was 0.52 (+0.35) (median 0.5; range 0.1-1; interquartile range (IQR) 0.3-0.8) and improved to 0.39 (+0.39) (median 0.4; range 0.1-1; IQR 0.2-0.5) by the end of the follow-up (p = 0.038). Subfoveal choroidal thickness was 202.8 (+60.3) μm (median 218; range 81-285; IQR 146-258). Statistical mixed effects model demonstrated an association between rate of improvement of visual acuity with subfoveal choroidal thickness after 24 months (p<0.001) (95% confidence interval 0.0002-0.0001 logMAR month μm); higher thickness values were correlated with better visual acuity.
Conclusions
Thicker subfoveal choroid was associated with better visual outcomes in patients with type 1 CNV due to nAMD following a strict PRN regimen with intravitreal ranibizumab at 24 months of follow-up.</description><identifier>ISSN: 1120-6721</identifier><identifier>EISSN: 1724-6016</identifier><identifier>DOI: 10.5301/ejo.5000860</identifier><identifier>PMID: 27646337</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - therapeutic use ; Choroid - pathology ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - etiology ; Choroidal Neovascularization - pathology ; Choroidal Neovascularization - physiopathology ; Cross-Sectional Studies ; Female ; Humans ; Intravitreal Injections ; Linear Models ; Longitudinal Studies ; Macular Degeneration - complications ; Macular Degeneration - drug therapy ; Macular Degeneration - pathology ; Macular Degeneration - physiopathology ; Male ; Prognosis ; Ranibizumab - therapeutic use ; Retrospective Studies ; Tomography, Optical Coherence ; Visual Acuity - physiology</subject><ispartof>European journal of ophthalmology, 2017-03, Vol.27 (2), p.196-200</ispartof><rights>2017 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c322t-8cde630724b429bf337daeef68df4d671fedfaf277ef9b973c2d74c8c71167283</citedby><cites>FETCH-LOGICAL-c322t-8cde630724b429bf337daeef68df4d671fedfaf277ef9b973c2d74c8c71167283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.5301/ejo.5000860$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.5301/ejo.5000860$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21799,27903,27904,43600,43601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27646337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hernández-Martínez, Pablo</creatorcontrib><creatorcontrib>Dolz-Marco, Rosa</creatorcontrib><creatorcontrib>Hervás-Marín, David</creatorcontrib><creatorcontrib>Andreu-Fenoll, Maria</creatorcontrib><creatorcontrib>Gallego-Pinazo, Roberto</creatorcontrib><creatorcontrib>Arévalo, José Fernando</creatorcontrib><title>Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration</title><title>European journal of ophthalmology</title><addtitle>Eur J Ophthalmol</addtitle><description>Purpose
To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD).
Methods
This was a retrospective, longitudinal, cross-sectional study including patients diagnosed with nAMD type 1 lesions managed with intravitreal injections of ranibizumab in a PRN strategy during 24 months. Retrospective chart review of patients with type 1 CNV recording the visual acuity, number of intravitreal injections, multimodal imaging data, and follow-up period was performed. Subfoveal choroidal thickness was measured using enhanced depth imaging scans obtained with spectral-domain optical coherence tomography.
Results
Twenty-five eyes of 21 patients were included. The mean baseline logMAR best-corrected visual acuity was 0.52 (+0.35) (median 0.5; range 0.1-1; interquartile range (IQR) 0.3-0.8) and improved to 0.39 (+0.39) (median 0.4; range 0.1-1; IQR 0.2-0.5) by the end of the follow-up (p = 0.038). Subfoveal choroidal thickness was 202.8 (+60.3) μm (median 218; range 81-285; IQR 146-258). Statistical mixed effects model demonstrated an association between rate of improvement of visual acuity with subfoveal choroidal thickness after 24 months (p<0.001) (95% confidence interval 0.0002-0.0001 logMAR month μm); higher thickness values were correlated with better visual acuity.
Conclusions
Thicker subfoveal choroid was associated with better visual outcomes in patients with type 1 CNV due to nAMD following a strict PRN regimen with intravitreal ranibizumab at 24 months of follow-up.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Choroid - pathology</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - etiology</subject><subject>Choroidal Neovascularization - pathology</subject><subject>Choroidal Neovascularization - physiopathology</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Linear Models</subject><subject>Longitudinal Studies</subject><subject>Macular Degeneration - complications</subject><subject>Macular Degeneration - drug therapy</subject><subject>Macular Degeneration - pathology</subject><subject>Macular Degeneration - physiopathology</subject><subject>Male</subject><subject>Prognosis</subject><subject>Ranibizumab - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Tomography, Optical Coherence</subject><subject>Visual Acuity - physiology</subject><issn>1120-6721</issn><issn>1724-6016</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkEtPwzAQhC0EoqVw4o58REIptpPaybFqy0MqD6HCNXLsdZqSxpWdIPXfY5TCidOuVt-OZgahS0rGk5jQW9jY8YQQknJyhIZUsCTihPLjsFNGIi4YHaAz7zeEMJIl7BQNmOAJj2MxRNvZ2jpbaVnj1bpSnw14j2Wj8Uflu3B8dbZsrK88rhq82u8AU7wEX9kGzzvArcXPYL-kV10tHZ6WEL1BLVvQ-En2tzmU0ICTbfg5RydG1h4uDnOE3u8Wq9lDtHy5f5xNl5GKGWujVGngMQlJioRlhQlOtQQwPNUm0VxQA9pIw4QAkxWZiBXTIlGpEpSGuGk8Qje9rnLWewcm37lqK90-pyT_KS0PpeWH0gJ91dO7rtiC_mN_WwrAdQ94WUK-sZ1rgvt_tb4BbyN1jA</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Hernández-Martínez, Pablo</creator><creator>Dolz-Marco, Rosa</creator><creator>Hervás-Marín, David</creator><creator>Andreu-Fenoll, Maria</creator><creator>Gallego-Pinazo, Roberto</creator><creator>Arévalo, José Fernando</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170301</creationdate><title>Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration</title><author>Hernández-Martínez, Pablo ; Dolz-Marco, Rosa ; Hervás-Marín, David ; Andreu-Fenoll, Maria ; Gallego-Pinazo, Roberto ; Arévalo, José Fernando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-8cde630724b429bf337daeef68df4d671fedfaf277ef9b973c2d74c8c71167283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Choroid - pathology</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - etiology</topic><topic>Choroidal Neovascularization - pathology</topic><topic>Choroidal Neovascularization - physiopathology</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Linear Models</topic><topic>Longitudinal Studies</topic><topic>Macular Degeneration - complications</topic><topic>Macular Degeneration - drug therapy</topic><topic>Macular Degeneration - pathology</topic><topic>Macular Degeneration - physiopathology</topic><topic>Male</topic><topic>Prognosis</topic><topic>Ranibizumab - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Tomography, Optical Coherence</topic><topic>Visual Acuity - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hernández-Martínez, Pablo</creatorcontrib><creatorcontrib>Dolz-Marco, Rosa</creatorcontrib><creatorcontrib>Hervás-Marín, David</creatorcontrib><creatorcontrib>Andreu-Fenoll, Maria</creatorcontrib><creatorcontrib>Gallego-Pinazo, Roberto</creatorcontrib><creatorcontrib>Arévalo, José Fernando</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hernández-Martínez, Pablo</au><au>Dolz-Marco, Rosa</au><au>Hervás-Marín, David</au><au>Andreu-Fenoll, Maria</au><au>Gallego-Pinazo, Roberto</au><au>Arévalo, José Fernando</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration</atitle><jtitle>European journal of ophthalmology</jtitle><addtitle>Eur J Ophthalmol</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>27</volume><issue>2</issue><spage>196</spage><epage>200</epage><pages>196-200</pages><issn>1120-6721</issn><eissn>1724-6016</eissn><abstract>Purpose
To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD).
Methods
This was a retrospective, longitudinal, cross-sectional study including patients diagnosed with nAMD type 1 lesions managed with intravitreal injections of ranibizumab in a PRN strategy during 24 months. Retrospective chart review of patients with type 1 CNV recording the visual acuity, number of intravitreal injections, multimodal imaging data, and follow-up period was performed. Subfoveal choroidal thickness was measured using enhanced depth imaging scans obtained with spectral-domain optical coherence tomography.
Results
Twenty-five eyes of 21 patients were included. The mean baseline logMAR best-corrected visual acuity was 0.52 (+0.35) (median 0.5; range 0.1-1; interquartile range (IQR) 0.3-0.8) and improved to 0.39 (+0.39) (median 0.4; range 0.1-1; IQR 0.2-0.5) by the end of the follow-up (p = 0.038). Subfoveal choroidal thickness was 202.8 (+60.3) μm (median 218; range 81-285; IQR 146-258). Statistical mixed effects model demonstrated an association between rate of improvement of visual acuity with subfoveal choroidal thickness after 24 months (p<0.001) (95% confidence interval 0.0002-0.0001 logMAR month μm); higher thickness values were correlated with better visual acuity.
Conclusions
Thicker subfoveal choroid was associated with better visual outcomes in patients with type 1 CNV due to nAMD following a strict PRN regimen with intravitreal ranibizumab at 24 months of follow-up.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>27646337</pmid><doi>10.5301/ejo.5000860</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1120-6721 |
| ispartof | European journal of ophthalmology, 2017-03, Vol.27 (2), p.196-200 |
| issn | 1120-6721 1724-6016 |
| language | eng |
| recordid | cdi_crossref_primary_10_5301_ejo_5000860 |
| source | MEDLINE; SAGE Complete |
| subjects | Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Choroid - pathology Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Choroidal Neovascularization - pathology Choroidal Neovascularization - physiopathology Cross-Sectional Studies Female Humans Intravitreal Injections Linear Models Longitudinal Studies Macular Degeneration - complications Macular Degeneration - drug therapy Macular Degeneration - pathology Macular Degeneration - physiopathology Male Prognosis Ranibizumab - therapeutic use Retrospective Studies Tomography, Optical Coherence Visual Acuity - physiology |
| title | Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T13%3A00%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Choroidal%20Thickness%20and%20Visual%20Prognosis%20in%20Type%201%20Lesion%20Due%20to%20Neovascular%20Age-Related%20Macular%20Degeneration&rft.jtitle=European%20journal%20of%20ophthalmology&rft.au=Hern%C3%A1ndez-Mart%C3%ADnez,%20Pablo&rft.date=2017-03-01&rft.volume=27&rft.issue=2&rft.spage=196&rft.epage=200&rft.pages=196-200&rft.issn=1120-6721&rft.eissn=1724-6016&rft_id=info:doi/10.5301/ejo.5000860&rft_dat=%3Csage_cross%3E10.5301_ejo.5000860%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27646337&rft_sage_id=10.5301_ejo.5000860&rfr_iscdi=true |